Gallant Therapeutics Raises Over $15 Million In Series A Funding To Advance Pipeline Of "Off-The-Shelf" Stem Cell Therapies For Pets
Amount Raised
$15 Million
Round Type
Series A
San DiegoOtherBiotechnologyHealth CareTherapeuticsDescription
Gallant Therapeutics, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million. The financing round, led by BOLD Capital and joined by new investors Digitalis Ventures and Hill Creek Partners, positions Gallant for a transformative phase of growth as they advance towards conditional FDA approval of their leading therapeutic candidate for Feline Chronic Gingivostomatitis (FCGS). Cindy Cole of Digitalis Ventures will join as a board observer alongside a new independent director who will join existing board members Teymour Boutros-Ghali, Linda Black, Richard Jennings, Darryl Rawlings, and James Ratigan Sr.
Who to call at Gallant, and when
A new round usually means Gallant is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Gallant raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gallant, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gallant. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gallant raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGallant raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.